San Diego, CA — October 9, 2018 — Poseida Therapeutics Inc., a San Diego-based company translating best-in-class gene engineering technologies into lifesaving cell therapies, today announced Marcy Graham has joined the company as vice president of corporate affairs. In this role, Ms. Graham will oversee investor relations, corporate communications and other functions within the organization.
“Marcy brings extensive knowledge and leadership experience across an array of communications and externally facing functions central to building strong relationships both with investors, as well as with the public,” said Eric Ostertag, M.D., Ph.D., chief executive officer at Poseida. “With her exceptional track record at fast-growing life science companies, Marcy is a key addition to our team as we enter into our next stage of corporate growth.”
Ms. Graham has nearly two decades of experience in corporate affairs, including 15 years of specialized experience with biotechnology and pharmaceutical companies. Most recently she served as vice president of investor relations and corporate communications at Mirati Therapeutics and aTyr Pharma, taking the latter public with an initial public offering in 2015. Previously, Ms. Graham led investor relations and corporate communications for Ambit Biosciences, where she directed communications strategy around the company’s initial public offering and into its eventual acquisition by Daiichi Sankyo in 2014. Earlier in her career, she oversaw investor relations and corporate communications functions at both Sequenom and Genoptix. Ms. Graham attended the University of New Mexico, where she earned an M.B.A. from the Anderson School of Management and a B.A. in journalism. She also completed the Strategic Financial Leadership Program at the Stanford Graduate School of Business Executive Education.
About Poseida Therapeutics Inc.
Poseida Therapeutics is translating best-in-class gene engineering technologies into lifesaving cell therapies. The company is developing CAR T-cell immunotherapies for multiple myeloma, prostate and other cancer types, as well as gene therapies for orphan diseases. P-BCMA-101 is Poseida’s lead CAR-T therapy currently in Phase 1 clinical development for the treatment of multiple myeloma. Poseida has assembled a suite of industry-leading gene engineering technologies, including the piggyBac™ DNA Modification System, TAL-CLOVER™ and Cas-CLOVER™ site-specific nucleases, and Footprint-Free™ Gene Editing (FFGE). For more information, visit www.poseida.com.
Corporate Communications Contacts:
VP, Corporate Affairs
Poseida Therapeutics, Inc.